{"ticker": {"uuid": "7a7c3a84-b603-4112-9ad7-5b3a751e1ed9", "symbol": "APGE", "name": "Apogee Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Apogee Therapeutics stock hits all-time high at 134.34 USD", "summary": "Apogee Therapeutics stock reached an all-time high of $134.34 USD, marking a significant milestone with a 243% increase over the past year and a market capitalization of $10.05 billion. The company is set to be acquired by AbbVie for $135.11 per share, following advancements in i", "url": "https://www.investing.com/news/company-news/apogee-therapeutics-stock-hits-alltime-high-at-13434-usd-93CH-4804058", "source_name": "Investing.com", "published_at": "2026-07-21T20:11:17", "published_display": "21 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?", "summary": "", "url": "https://finance.yahoo.com/m/2f0e4386-3000-3b6a-b1f8-61c2d38044c1/how-will-abbvie%27s-%2410.9.html", "source_name": "Motley Fool", "published_at": "2026-07-20T01:05:00+00:00", "published_display": "20 Jul 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) Proxy filing Summary", "summary": "This article summarizes the proxy filing for Apogee Therapeutics (APGE), detailing the upcoming annual meeting on June 9, 2026. Key agenda items include the election of three Class III directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote o", "url": "https://quartr.com/events/apogee-therapeutics-apge-proxy-filing_FLIgS08a", "source_name": "Quartr", "published_at": "2026-07-18T03:10:54", "published_display": "18 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com", "summary": "This article reports on a Form 4 filing for Apogee Therapeutics Inc. for July 16, as published by Investing.com. It is a brief announcement without further details regarding the contents of the filing. The article indicates the stock symbol APGE.", "url": "https://za.investing.com/news/stock-market-news/form-4-apogee-therapeutics-inc-for-16-july-93CH-4373482", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T06:11:52", "published_display": "17 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CMO donates 8,000 shares to donor advised fund", "summary": "Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a gift of 8,000 shares of common stock on July 14, 2026. The shares were transferred to a donor advised fund as a non-market disposition at $0.00 per share. Following this transaction, Dambkowski directly holds", "url": "https://www.stocktitan.net/sec-filings/APGE/form-4-apogee-therapeutics-inc-insider-trading-activity-41b09de07530.html", "source_name": "Stock Titan", "published_at": "2026-07-17T00:09:29", "published_display": "17 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQZUgzN3kyZWZYcGZSUTQyRXZlUWV0azRvQnBlZFhxUDRZeGd3czBSQWlXN0xIajIzVzIwRGlxYU1aSDRINkpXQnZkQTBhcFNNcnVROXJxWTJ0VkxFRmN5bEZacHBXZEt3S2t2NVF5dGJKeG5aT08tc1M0cFlwOEMwN2otd1lmb2ZacDNDYTFYcDFKTXRNUEJTY284UVRKTDNkeERERjFHZ3Y4YmVhTmp6c01uTmMyUQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T14:44:00+00:00", "published_display": "15 Jul 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics stock hits all-time high at 133.88 USD By Investing.com", "summary": "Apogee Therapeutics stock reached an all-time high of $133.88, with a market capitalization of $10.02 billion, reflecting a 250% return over the past year. This surge is despite InvestingPro data suggesting the stock might be overvalued and in overbought territory, according to i", "url": "https://ng.investing.com/news/stock-market-news/apogee-therapeutics-stock-hits-alltime-high-at-13388-usd-93CH-2597402", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T05:40:15", "published_display": "15 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (NASDAQ: APGE) backs AbbVie\u2019s $135.11\u2011per\u2011share all\u2011cash deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNTmt4djFNU0VVT19GcjF6cHJBZ2NCUWZZdW4xNndLTmhPOEQzYXVmSjNSSDhWNnJfTTBGM2FWZlZJYnowaFRuVEhpbUVLWVNIVHhxbktENVNxaURmblRSaE5rU1B0MDhIc0NVZ3VqZnhBcHIzWng4VnZSWktfN1JlaERzN0ZkRm1FX2tjVHNVTGo1Y0EtTFR2eUdCMnQ3RXhQRXE3Q2Rqa0EyRS0yRGtVMEJ2WDV2d00?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T21:15:54+00:00", "published_display": "13 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics stock hits all-time high at 133.88 USD", "summary": "Apogee Therapeutics (APGE) stock reached an all-time high of $133.88, reflecting a 250% return over the past year and a market capitalization of $10.02 billion. Despite its strong performance, InvestingPro suggests the stock might be overvalued, with the RSI indicating it's in ov", "url": "https://www.investing.com/news/company-news/apogee-therapeutics-stock-hits-alltime-high-at-13388-usd-93CH-4789131", "source_name": "Investing.com", "published_at": "2026-07-13T20:10:38", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What This Apogee Insider Move Might Mean After a 247% Stock Run", "summary": "", "url": "https://finance.yahoo.com/m/8f9cbad2-f6b9-3157-9d05-f1d29f6d9a8f/what-this-apogee-insider-move.html", "source_name": "Motley Fool", "published_at": "2026-07-12T17:53:27+00:00", "published_display": "12 Jul 2026 17:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (APGE)", "summary": "This article analyzes momentum shifts for Apogee Therapeutics Inc. (NASDAQ: APGE), noting a near-term neutral sentiment amidst stronger mid and long-term outlooks. It identifies no resistance levels above the current price, suggesting upside potential. The report provides detaile", "url": "https://news.stocktradersdaily.com/news_release/43/Understanding_Momentum_Shifts_in_APGE_071226053801_1783849081.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T05:38:00", "published_display": "12 Jul 2026 05:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty", "summary": "", "url": "https://finance.yahoo.com/m/65356430-b60a-31e3-a85d-12925b4512e4/abbvie-is-already-a-dividend.html", "source_name": "Motley Fool", "published_at": "2026-07-12T00:35:00+00:00", "published_display": "12 Jul 2026 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE)", "summary": "Michael Henderson, CEO of Apogee Therapeutics Inc (APGE), sold 20,000 shares of the company on July 8, 2026. This transaction follows a pattern where Henderson has sold a total of 280,000 shares over the past year with no corresponding purchases. The article highlights that there", "url": "https://www.gurufocus.com/news/8954353/ceo-michael-henderson-sells-20000-shares-of-apogee-therapeutics-inc-apge", "source_name": "GuruFocus", "published_at": "2026-07-11T02:09:51", "published_display": "11 Jul 2026 02:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?", "summary": "Apogee Therapeutics (APGE) has attracted attention due to significant share price increases recently, prompting investors to re-evaluate its risk and return profile. Currently trading at $133.57, the stock has seen substantial year-to-date and one-year returns. Its price-to-book ", "url": "https://uk.finance.yahoo.com/news/apogee-therapeutics-apge-jumps-focus-221425662.html", "source_name": "Market source", "published_at": "2026-07-11T00:14:00", "published_display": "11 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock", "summary": "Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of company stock worth $2.67 million and gifted 75,046 shares to a donor-advised fund. These transactions occurred as Apogee Therapeutics stock trades near its 52-week high, having gained 250% in the last year, and foll", "url": "https://www.investing.com/news/insider-trading-news/apogee-therapeutics-ceo-michael-henderson-sells-267m-in-stock-93CH-4787177", "source_name": "Investing.com", "published_at": "2026-07-11T00:09:52", "published_display": "11 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Apogee Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Apogee Therapeutics Inc. on July 10. The filing, associated with the stock symbol APGE, was published on Investing.com and includes financial market data such as indices, commodities, and currency exchange rates.", "url": "https://ng.investing.com/news/stock-market-news/form-4-apogee-therapeutics-inc-for-10-july-93CH-2595741", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T00:09:51", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CEO logs stock sale and 75,046-share charitable gift", "summary": "Apogee Therapeutics CEO Michael Thomas Henderson reported a sale of 20,000 shares of common stock at a weighted average price of $133.63, executed under a pre-arranged Rule 10b5-1 trading plan. Additionally, he made a charitable gift of 75,046 shares to a donor-advised fund. Foll", "url": "https://www.stocktitan.net/sec-filings/APGE/form-4-apogee-therapeutics-inc-insider-trading-activity-09e54e21edd9.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:51", "published_display": "11 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie to buy Apogee Therapeutics for $10.9 billion in cash", "summary": "AbbVie announced its intent to acquire Apogee Therapeutics for $10.9 billion in cash. This acquisition is significant for AbbVie's portfolio, enhancing its presence in the therapeutics market through Apogee's pipeline. The deal highlights continued consolidation and strategic inv", "url": "https://www.msn.com/en-us/money/mergers-and-acquisitions/abbvie-to-buy-apogee-therapeutics-for-10-9-billion-in-cash/ar-AA26g90g?ocid=TobArticle", "source_name": "MSN", "published_at": "2026-07-10T11:40:11", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wellington-affiliates report 564,326 APGE shares (APGE) ownership update", "summary": "Wellington Management-affiliated entities have filed a Schedule 13G/A, reporting beneficial ownership of 564,326 shares (0.91%) of Apogee Therapeutics, Inc. (APGE) common stock as of June 30, 2026. The filing indicates shared voting power of 452,388 shares and shared dispositive ", "url": "https://www.stocktitan.net/sec-filings/APGE/schedule-13g-a-apogee-therapeutics-inc-amended-passive-investment-dis-99182ab9dd72.html", "source_name": "Stock Titan", "published_at": "2026-07-08T16:40:47", "published_display": "08 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price boosts Apogee Therapeutics holding to 772,969 shares (NASDAQ: APGE)", "summary": "T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 772,969 shares of Apogee Therapeutics common stock, representing 1.3% of the class as of June 30, 2026. This information was disclosed in an Amendment No. 2 to a Schedule 13G/A filing, signed on July", "url": "https://www.stocktitan.net/sec-filings/APGE/schedule-13g-a-apogee-therapeutics-inc-amended-passive-investment-dis-46ccae81442a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T15:40:47", "published_display": "08 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 2.49M Apogee Therapeutics shares (NASDAQ: APGE)", "summary": "FMR LLC has filed a Schedule 13G/A, reporting beneficial ownership of 2,493,136.73 shares of Apogee Therapeutics (NASDAQ: APGE) common stock, which represents 4.0% of the class. The filing indicates FMR LLC has sole dispositive power over all these shares and sole voting power ov", "url": "https://www.stocktitan.net/sec-filings/APGE/schedule-13g-a-apogee-therapeutics-inc-amended-passive-investment-dis-51cdb15733aa.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:09:23", "published_display": "08 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article provides the enterprise value to EBIT forward for Apogee Therapeutics, Inc. (NASDAQ: APGE) based on data from TradingView. It indicates that the data for the given period shows a specific value, change, and percentage change. The article appears to be a financial sna", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:10:00", "published_display": "07 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This page from TradingView provides financial information for Apogee Therapeutics, Inc. under the NASDAQ:APGE ticker. It specifically highlights the \"Price to earnings forward\" metric and indicates that the market is currently closed with no trades. The content is primarily a pla", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T03:40:36", "published_display": "06 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article shows the enterprise value to EBITDA forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content itself is very minimal, primarily serving a", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T11:39:40", "published_display": "05 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics | SCHEDULE 13G/A: Others", "summary": "This article provides an SEC filing snippet for Apogee Therapeutics, specifically referencing a SCHEDULE 13G/A document. The content of the document itself is not provided, only its existence is noted.", "url": "https://www.moomoo.com/news/notice/306883578/apogee-therapeutics-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-07-05T10:40:36", "published_display": "05 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article focuses on the enterprise value to revenue forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data snippet or a headline from a financial platform like TradingView, providing a direct metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:11:06", "published_display": "05 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE - Apogee Therapeutics Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Apogee Therapeutics Inc (APGE), including its stock performance, market capitalization, key financial ratios, and institutional ownership. It highlights that the company currently has no sales and is operating at a net loss", "url": "https://finviz.com/stock?t=APGE&p=d&ty=rv&b=2", "source_name": "Finviz", "published_at": "2026-07-03T22:10:12", "published_display": "03 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article focuses on the \"Price to sales forward\" metric for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical data, and forecasts. The page structure also ", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T04:39:38", "published_display": "03 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CMO sells shares, exercises options under 10b5-1 plan", "summary": "Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported an option exercise and a related sale of company shares. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved exercising options for 4,125 shares at $22.86 each and selling 5,500 s", "url": "https://www.stocktitan.net/sec-filings/APGE/form-4-apogee-therapeutics-inc-insider-trading-activity-5cf914ef3dec.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:39:38", "published_display": "03 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics stock hits all-time high at 133.32 USD", "summary": "Apogee Therapeutics' stock has reached an all-time high of $133.32, with a soaring 1-year return of nearly 200%, reflecting significant investor confidence. This surge comes amid news of an acquisition by AbbVie for $135.11 per share and ongoing strategic developments like antibo", "url": "https://www.investing.com/news/company-news/apogee-therapeutics-stock-hits-alltime-high-at-13332-usd-93CH-4773304", "source_name": "Investing.com", "published_at": "2026-07-02T22:10:12", "published_display": "02 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Gives SBIO Its Best Month Since 2023", "summary": "The ALPS Medical Breakthroughs ETF (SBIO) experienced its best single month since December 2023, returning 18.7% in June, primarily driven by biotech stock performance. Key contributors included Apogee, Definium, and Oruka, with significant surges due to drug trial results and a ", "url": "https://etfdb.com/etf-building-blocks-content-hub/thanks-biotech-sbio-sees-best-month-2023", "source_name": "ETF Database", "published_at": "2026-07-02T17:39:38", "published_display": "02 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CEO executes 80,000-share planned stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVXdqZ2RPZXZrXzU3OGJTaC1zWnFCWnRkSUlkTEpFb3VWa0xoN2NlRDlGbFpmellUZVZSNGtRbEMtOUhhZlZXbFkxdGZoRjJCeVd2d3VnOWcxUDhjeU9OU0otUTlGVTZlb1Q3WV9yWG5JLWtLVEtFNUt4dDRwSUpSZjk1RVpFZmdjc3lHSWxvTV9oQlZ3amRkSW81aUZiMUlSYU93UWp0QlhNTjl0SW9sWDNNdC16ZDN3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CMO sells 26,400 shares in planned open-market trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaFRTdlZUc0txazdKWFlpNE96ZHp1ZENsNnZzejJSZ0VEQmYwV2V0OVJQSVp1NW9JVXdxSzVQY0ZndjVDbXoxd19PdnRSbzFqc1pqZzBLNVlQOWhsTDVXbk9tMDgtRmhuVFlxUHhEdWM1RHFILU5hS3VlZUNlYWVsdTZUV3ZBdkdkdFZNa0QxSjRpN0V6XzFEdFhUU1BHRnN2TWFGaVNGZUIyUmlZM1JQRHliTWlBWjZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics : APGE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE12NngzSjFPcGVWNlRkUThyc2NBUllmbWpxT01Yb2dEWmtlRFQ1MlQxMk5qTWJPb0dOR2Z6WlZlUG9iYU93WkNyRGxpOUhrZw?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPZkQ4LXlCSGQ3SGFDOE9rb1ZnNW9rSGE2dHR2OG1QQTdhUWVnSmlzcjVfNTdlUzRsUlB1WElrZXZKTktjQlRySzlqOHUxbFdHZmJSUXBrYmpidFdlWE0zajJHQWZYdkI3UnNxVHlkaVlsRFZUelItY3d2UU00WXoyUDNWUTVpdlI4SmtTUndDOGZIUmk1cHVOS0xsVlJ4QjAzRG9LVy11bzU2bE9hVDlaeXVqZU5hSmRPNURxaUs5M1E5cE1aYjYwdHV1QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Surges On Trial Win And $1.3B Blackstone Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPLWRVTlA1WWZ3QTVsc3ZWZXpyWFRzNnNyUzhqVmtadk14SC13S0dzVDJRelZZWUs5V3pHcHFraTVLWk55a3EyazZmZjlyOW5TVlZjRVQxbDI3cTF2eElfa1RnZnFGUFRJUHNnWWZrQUdDcEhVamE1aVZOTVEtZGJhcGVyT2Y?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Rallies As Street Backs Zumilokibart Breakthrough", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPTnpQZnBqRHNKbVI1UVlQYmhDVzdtUmp2ZWZPd1dmTV9GcXI2TEVMRjNidzI4eW9VUXNsZ2ZRbThaNHI0RUlXejBwWC16T0E0cmN4cGl6d29raWxOSG5UV1dFOWVzLXNGcmk5SG11SnF6N3ZEbnV5MVp1THVrUkVXbA?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie to acquire Apogee Therapeutics (NASDAQ: APGE) in $10.9B cash deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNS3J2MlZQNThSU0diTzhkVE41MGdObDhTRlkyVUJMV3BGdXN1WXNWa3phOWlBUmlMVlBxTGxCMHRUbHNBRFg0d0ZiZlNpSGxvTjlnS3B4Nms4T1ZCWlBBUWVOeUdRX3RFelplTDJ0WjB5V2VtN3hxb2c3SHBrMWV6NFRSaVYzSEZzZWVNR0M1SFViVHRDaDh4OEZOQUU5dnlRVFplMUZSOUwyeW45VDZUejdB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE (NASDAQ: APGE) files Form 144 listing recent 10b5-1 sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPYURqdHJzZ1Y1WmJYNTVWcTg5R3A0emYxV24yVk5XbE9LaFVRYUV2cUhjVVhmT0FCYmhockw4ZXEzNmJOdFJCTnhSSXEzbmw2cjZ1V2ZDSEl2WWZSWnVJa3pxdUszV25ld3ltZ2gzQjNuMHpMNHYxVEVuc0RqaUJRMFZPYUpuNFAwUUFkQ1c2bFFUNHAxOHhNcWR5RG15R3k5MkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVGpFMmJScFBSTEU5SkZXeEluaFQ4cHBPY1JmeXVUc2w5cDEyMHpQbUVpRE5GMl9wbUhqRzZqUFlnMkRnWERhNnItVzVmWDd0WWZmRU1nRDNadWNnQUhVNTN4NXhkaFJSOXVNZFRyb2pyalI5VGZRZFp0ODVxWURlZ0w0dDJpNUl6Q2Fta0tDTWQtRko4NDZR?oc=5", "source_name": "CNBC", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Climbs As Zumilokibart Data And Blackstone Deal Reprice The Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNZ1lwWVpseHo5MDVFRjVsRHBhSjVXX1FWbWd2ajlPZ3JWX3YwNWZyTk83elU2NG5oczBfU2tmN1p1blFSNG14UHBwZk1Yc0J4NVN0ZkpCX2dGcGpjMndMbHZJRklpTy1zNGlyTkVaN1JBZzJfV3FLSWFVSFV0SkNPRWZlemhmcnV2?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOZk93bkRYeG9lZnlUWGlfWWsweDVFSGRXV1NuWFZnaW5admhybl9IcXpXNS00NmI1QU5FM2VVRW9wQzBZVkQ0T25rcHoyOU4xeWtQc0cyaWQwZXdQZ1JWZUFINHdfRkJIWG1fUl83ekZsVE1Mb3Rac3Q0bWszdG8tbjJyR0x5cFZzZ1lwNS0zOC1lQUNtLWttcTlzUDZKMmExc3c?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Climbs As Wall Street Bets On Zumilokibart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPTkd6a1RVMEFXLS1EdXlzUzItbTYtS1JfeUVGMWk3NE1SOVp4ellrLVBueTVieXdQY25ZUFc0bFJuTmlHRkFMa1ltMHFLTEtYcEFnYU1LQmc1azdHbWg2bmh1WWtZZ0oySU14Y25DaWVONkFMdUsxdmpONmRZdTgtSjR3?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) links 7,657-share option grant to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxONnAxQ0JuRGNJQjFqWC1XZ09XRGpMQkMzOGE3NVNuUUVsZkpOdEV2Z3pyWkNJTGs2Vy00Ym43RUhkV2pGdkhNVVpTLXFQWXNvUWhNVzZabVF5OUNsNS1UMnJubzZ5cHBzUmpYYXJMVEhyVTNJQnBWN1B0bi1rNEdPUm1GUm5uOUszX3lLaF9td3dGaHFINFBaM3JqY0VJR2RJRWdJQ2RUSzI0dWNYTXpaLXFMQVhyRDlx?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaEZIYnc0dXlYS0RKYmtFRU1EX20wVjVGT0x3Y3JzSUJ1SDBXbGFnbFItOENpbjNxd0xOTU1UdlBvNWdmYmg2a3FLbGxaVndFT2ZSUFQ1bF8xbnZlSktsenJtNGJ2VTNBM1BoTFhhNmh2cTUtTE5rXzdWMUI3b1NVSEZaZzJSR1BGUmVkZFpXeFc5MHJvbEVLZW5VOVI1Vk9YTkdVRUtVT3c?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech Apogee raises $403M after underwriters buy extra shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdnJPdWtaZmxWQVFqMmtnT1hwa2VrMW9CMkQtbnhmZTdXM0xDSngwX3VPdFRrenFVQ0pHVmRkRmtfZ2dIWjlacmlyTUhDTDRFMnRHRVBERm5QNUpzczA0RDJVZFUyUDZTdmJpcW9lbUs1bndfaklsRk1UZG1GZno0bHFIT0R3YnFwN2NReXZ5S1dheW9hZklWWEcxbTVNcGlHZXAtQlpoS2Y4bEhhX0hHekNZSXNYTFd1cVRJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Apogee Therapeutics stock hits all-time high at 134.34 USD", "summary": "Apogee Therapeutics stock reached an all-time high of $134.34 USD, marking a significant milestone with a 243% increase over the past year and a market capitalization of $10.05 billion. The company is set to be acquired by AbbVie for $135.11 per share, following advancements in i", "url": "https://www.investing.com/news/company-news/apogee-therapeutics-stock-hits-alltime-high-at-13434-usd-93CH-4804058", "source_name": "Investing.com", "published_at": "2026-07-21T20:11:17", "published_display": "21 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?", "summary": "", "url": "https://finance.yahoo.com/m/2f0e4386-3000-3b6a-b1f8-61c2d38044c1/how-will-abbvie%27s-%2410.9.html", "source_name": "Motley Fool", "published_at": "2026-07-20T01:05:00+00:00", "published_display": "20 Jul 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) Proxy filing Summary", "summary": "This article summarizes the proxy filing for Apogee Therapeutics (APGE), detailing the upcoming annual meeting on June 9, 2026. Key agenda items include the election of three Class III directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote o", "url": "https://quartr.com/events/apogee-therapeutics-apge-proxy-filing_FLIgS08a", "source_name": "Quartr", "published_at": "2026-07-18T03:10:54", "published_display": "18 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com", "summary": "This article reports on a Form 4 filing for Apogee Therapeutics Inc. for July 16, as published by Investing.com. It is a brief announcement without further details regarding the contents of the filing. The article indicates the stock symbol APGE.", "url": "https://za.investing.com/news/stock-market-news/form-4-apogee-therapeutics-inc-for-16-july-93CH-4373482", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T06:11:52", "published_display": "17 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CMO donates 8,000 shares to donor advised fund", "summary": "Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a gift of 8,000 shares of common stock on July 14, 2026. The shares were transferred to a donor advised fund as a non-market disposition at $0.00 per share. Following this transaction, Dambkowski directly holds", "url": "https://www.stocktitan.net/sec-filings/APGE/form-4-apogee-therapeutics-inc-insider-trading-activity-41b09de07530.html", "source_name": "Stock Titan", "published_at": "2026-07-17T00:09:29", "published_display": "17 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQZUgzN3kyZWZYcGZSUTQyRXZlUWV0azRvQnBlZFhxUDRZeGd3czBSQWlXN0xIajIzVzIwRGlxYU1aSDRINkpXQnZkQTBhcFNNcnVROXJxWTJ0VkxFRmN5bEZacHBXZEt3S2t2NVF5dGJKeG5aT08tc1M0cFlwOEMwN2otd1lmb2ZacDNDYTFYcDFKTXRNUEJTY284UVRKTDNkeERERjFHZ3Y4YmVhTmp6c01uTmMyUQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T14:44:00+00:00", "published_display": "15 Jul 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics stock hits all-time high at 133.88 USD By Investing.com", "summary": "Apogee Therapeutics stock reached an all-time high of $133.88, with a market capitalization of $10.02 billion, reflecting a 250% return over the past year. This surge is despite InvestingPro data suggesting the stock might be overvalued and in overbought territory, according to i", "url": "https://ng.investing.com/news/stock-market-news/apogee-therapeutics-stock-hits-alltime-high-at-13388-usd-93CH-2597402", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T05:40:15", "published_display": "15 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (NASDAQ: APGE) backs AbbVie\u2019s $135.11\u2011per\u2011share all\u2011cash deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNTmt4djFNU0VVT19GcjF6cHJBZ2NCUWZZdW4xNndLTmhPOEQzYXVmSjNSSDhWNnJfTTBGM2FWZlZJYnowaFRuVEhpbUVLWVNIVHhxbktENVNxaURmblRSaE5rU1B0MDhIc0NVZ3VqZnhBcHIzWng4VnZSWktfN1JlaERzN0ZkRm1FX2tjVHNVTGo1Y0EtTFR2eUdCMnQ3RXhQRXE3Q2Rqa0EyRS0yRGtVMEJ2WDV2d00?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T21:15:54+00:00", "published_display": "13 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics stock hits all-time high at 133.88 USD", "summary": "Apogee Therapeutics (APGE) stock reached an all-time high of $133.88, reflecting a 250% return over the past year and a market capitalization of $10.02 billion. Despite its strong performance, InvestingPro suggests the stock might be overvalued, with the RSI indicating it's in ov", "url": "https://www.investing.com/news/company-news/apogee-therapeutics-stock-hits-alltime-high-at-13388-usd-93CH-4789131", "source_name": "Investing.com", "published_at": "2026-07-13T20:10:38", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This Apogee Insider Move Might Mean After a 247% Stock Run", "summary": "", "url": "https://finance.yahoo.com/m/8f9cbad2-f6b9-3157-9d05-f1d29f6d9a8f/what-this-apogee-insider-move.html", "source_name": "Motley Fool", "published_at": "2026-07-12T17:53:27+00:00", "published_display": "12 Jul 2026 17:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (APGE)", "summary": "This article analyzes momentum shifts for Apogee Therapeutics Inc. (NASDAQ: APGE), noting a near-term neutral sentiment amidst stronger mid and long-term outlooks. It identifies no resistance levels above the current price, suggesting upside potential. The report provides detaile", "url": "https://news.stocktradersdaily.com/news_release/43/Understanding_Momentum_Shifts_in_APGE_071226053801_1783849081.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T05:38:00", "published_display": "12 Jul 2026 05:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty", "summary": "", "url": "https://finance.yahoo.com/m/65356430-b60a-31e3-a85d-12925b4512e4/abbvie-is-already-a-dividend.html", "source_name": "Motley Fool", "published_at": "2026-07-12T00:35:00+00:00", "published_display": "12 Jul 2026 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE)", "summary": "Michael Henderson, CEO of Apogee Therapeutics Inc (APGE), sold 20,000 shares of the company on July 8, 2026. This transaction follows a pattern where Henderson has sold a total of 280,000 shares over the past year with no corresponding purchases. The article highlights that there", "url": "https://www.gurufocus.com/news/8954353/ceo-michael-henderson-sells-20000-shares-of-apogee-therapeutics-inc-apge", "source_name": "GuruFocus", "published_at": "2026-07-11T02:09:51", "published_display": "11 Jul 2026 02:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?", "summary": "Apogee Therapeutics (APGE) has attracted attention due to significant share price increases recently, prompting investors to re-evaluate its risk and return profile. Currently trading at $133.57, the stock has seen substantial year-to-date and one-year returns. Its price-to-book ", "url": "https://uk.finance.yahoo.com/news/apogee-therapeutics-apge-jumps-focus-221425662.html", "source_name": "Market source", "published_at": "2026-07-11T00:14:00", "published_display": "11 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock", "summary": "Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of company stock worth $2.67 million and gifted 75,046 shares to a donor-advised fund. These transactions occurred as Apogee Therapeutics stock trades near its 52-week high, having gained 250% in the last year, and foll", "url": "https://www.investing.com/news/insider-trading-news/apogee-therapeutics-ceo-michael-henderson-sells-267m-in-stock-93CH-4787177", "source_name": "Investing.com", "published_at": "2026-07-11T00:09:52", "published_display": "11 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Apogee Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Apogee Therapeutics Inc. on July 10. The filing, associated with the stock symbol APGE, was published on Investing.com and includes financial market data such as indices, commodities, and currency exchange rates.", "url": "https://ng.investing.com/news/stock-market-news/form-4-apogee-therapeutics-inc-for-10-july-93CH-2595741", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T00:09:51", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CEO logs stock sale and 75,046-share charitable gift", "summary": "Apogee Therapeutics CEO Michael Thomas Henderson reported a sale of 20,000 shares of common stock at a weighted average price of $133.63, executed under a pre-arranged Rule 10b5-1 trading plan. Additionally, he made a charitable gift of 75,046 shares to a donor-advised fund. Foll", "url": "https://www.stocktitan.net/sec-filings/APGE/form-4-apogee-therapeutics-inc-insider-trading-activity-09e54e21edd9.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:51", "published_display": "11 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie to buy Apogee Therapeutics for $10.9 billion in cash", "summary": "AbbVie announced its intent to acquire Apogee Therapeutics for $10.9 billion in cash. This acquisition is significant for AbbVie's portfolio, enhancing its presence in the therapeutics market through Apogee's pipeline. The deal highlights continued consolidation and strategic inv", "url": "https://www.msn.com/en-us/money/mergers-and-acquisitions/abbvie-to-buy-apogee-therapeutics-for-10-9-billion-in-cash/ar-AA26g90g?ocid=TobArticle", "source_name": "MSN", "published_at": "2026-07-10T11:40:11", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wellington-affiliates report 564,326 APGE shares (APGE) ownership update", "summary": "Wellington Management-affiliated entities have filed a Schedule 13G/A, reporting beneficial ownership of 564,326 shares (0.91%) of Apogee Therapeutics, Inc. (APGE) common stock as of June 30, 2026. The filing indicates shared voting power of 452,388 shares and shared dispositive ", "url": "https://www.stocktitan.net/sec-filings/APGE/schedule-13g-a-apogee-therapeutics-inc-amended-passive-investment-dis-99182ab9dd72.html", "source_name": "Stock Titan", "published_at": "2026-07-08T16:40:47", "published_display": "08 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price boosts Apogee Therapeutics holding to 772,969 shares (NASDAQ: APGE)", "summary": "T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 772,969 shares of Apogee Therapeutics common stock, representing 1.3% of the class as of June 30, 2026. This information was disclosed in an Amendment No. 2 to a Schedule 13G/A filing, signed on July", "url": "https://www.stocktitan.net/sec-filings/APGE/schedule-13g-a-apogee-therapeutics-inc-amended-passive-investment-dis-46ccae81442a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T15:40:47", "published_display": "08 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 2.49M Apogee Therapeutics shares (NASDAQ: APGE)", "summary": "FMR LLC has filed a Schedule 13G/A, reporting beneficial ownership of 2,493,136.73 shares of Apogee Therapeutics (NASDAQ: APGE) common stock, which represents 4.0% of the class. The filing indicates FMR LLC has sole dispositive power over all these shares and sole voting power ov", "url": "https://www.stocktitan.net/sec-filings/APGE/schedule-13g-a-apogee-therapeutics-inc-amended-passive-investment-dis-51cdb15733aa.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:09:23", "published_display": "08 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article provides the enterprise value to EBIT forward for Apogee Therapeutics, Inc. (NASDAQ: APGE) based on data from TradingView. It indicates that the data for the given period shows a specific value, change, and percentage change. The article appears to be a financial sna", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:10:00", "published_display": "07 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This page from TradingView provides financial information for Apogee Therapeutics, Inc. under the NASDAQ:APGE ticker. It specifically highlights the \"Price to earnings forward\" metric and indicates that the market is currently closed with no trades. The content is primarily a pla", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T03:40:36", "published_display": "06 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article shows the enterprise value to EBITDA forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content itself is very minimal, primarily serving a", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T11:39:40", "published_display": "05 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics | SCHEDULE 13G/A: Others", "summary": "This article provides an SEC filing snippet for Apogee Therapeutics, specifically referencing a SCHEDULE 13G/A document. The content of the document itself is not provided, only its existence is noted.", "url": "https://www.moomoo.com/news/notice/306883578/apogee-therapeutics-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-07-05T10:40:36", "published_display": "05 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article focuses on the enterprise value to revenue forward for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data snippet or a headline from a financial platform like TradingView, providing a direct metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:11:06", "published_display": "05 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE - Apogee Therapeutics Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Apogee Therapeutics Inc (APGE), including its stock performance, market capitalization, key financial ratios, and institutional ownership. It highlights that the company currently has no sales and is operating at a net loss", "url": "https://finviz.com/stock?t=APGE&p=d&ty=rv&b=2", "source_name": "Finviz", "published_at": "2026-07-03T22:10:12", "published_display": "03 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Apogee Therapeutics, Inc. \u2013 NASDAQ:APGE", "summary": "This article focuses on the \"Price to sales forward\" metric for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical data, and forecasts. The page structure also ", "url": "https://www.tradingview.com/symbols/NASDAQ-APGE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T04:39:38", "published_display": "03 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CMO sells shares, exercises options under 10b5-1 plan", "summary": "Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported an option exercise and a related sale of company shares. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved exercising options for 4,125 shares at $22.86 each and selling 5,500 s", "url": "https://www.stocktitan.net/sec-filings/APGE/form-4-apogee-therapeutics-inc-insider-trading-activity-5cf914ef3dec.html", "source_name": "Stock Titan", "published_at": "2026-07-03T00:39:38", "published_display": "03 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics stock hits all-time high at 133.32 USD", "summary": "Apogee Therapeutics' stock has reached an all-time high of $133.32, with a soaring 1-year return of nearly 200%, reflecting significant investor confidence. This surge comes amid news of an acquisition by AbbVie for $135.11 per share and ongoing strategic developments like antibo", "url": "https://www.investing.com/news/company-news/apogee-therapeutics-stock-hits-alltime-high-at-13332-usd-93CH-4773304", "source_name": "Investing.com", "published_at": "2026-07-02T22:10:12", "published_display": "02 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Gives SBIO Its Best Month Since 2023", "summary": "The ALPS Medical Breakthroughs ETF (SBIO) experienced its best single month since December 2023, returning 18.7% in June, primarily driven by biotech stock performance. Key contributors included Apogee, Definium, and Oruka, with significant surges due to drug trial results and a ", "url": "https://etfdb.com/etf-building-blocks-content-hub/thanks-biotech-sbio-sees-best-month-2023", "source_name": "ETF Database", "published_at": "2026-07-02T17:39:38", "published_display": "02 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CEO executes 80,000-share planned stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVXdqZ2RPZXZrXzU3OGJTaC1zWnFCWnRkSUlkTEpFb3VWa0xoN2NlRDlGbFpmellUZVZSNGtRbEMtOUhhZlZXbFkxdGZoRjJCeVd2d3VnOWcxUDhjeU9OU0otUTlGVTZlb1Q3WV9yWG5JLWtLVEtFNUt4dDRwSUpSZjk1RVpFZmdjc3lHSWxvTV9oQlZ3amRkSW81aUZiMUlSYU93UWp0QlhNTjl0SW9sWDNNdC16ZDN3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) CMO sells 26,400 shares in planned open-market trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaFRTdlZUc0txazdKWFlpNE96ZHp1ZENsNnZzejJSZ0VEQmYwV2V0OVJQSVp1NW9JVXdxSzVQY0ZndjVDbXoxd19PdnRSbzFqc1pqZzBLNVlQOWhsTDVXbk9tMDgtRmhuVFlxUHhEdWM1RHFILU5hS3VlZUNlYWVsdTZUV3ZBdkdkdFZNa0QxSjRpN0V6XzFEdFhUU1BHRnN2TWFGaVNGZUIyUmlZM1JQRHliTWlBWjZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics : APGE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE12NngzSjFPcGVWNlRkUThyc2NBUllmbWpxT01Yb2dEWmtlRFQ1MlQxMk5qTWJPb0dOR2Z6WlZlUG9iYU93WkNyRGxpOUhrZw?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPZkQ4LXlCSGQ3SGFDOE9rb1ZnNW9rSGE2dHR2OG1QQTdhUWVnSmlzcjVfNTdlUzRsUlB1WElrZXZKTktjQlRySzlqOHUxbFdHZmJSUXBrYmpidFdlWE0zajJHQWZYdkI3UnNxVHlkaVlsRFZUelItY3d2UU00WXoyUDNWUTVpdlI4SmtTUndDOGZIUmk1cHVOS0xsVlJ4QjAzRG9LVy11bzU2bE9hVDlaeXVqZU5hSmRPNURxaUs5M1E5cE1aYjYwdHV1QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Surges On Trial Win And $1.3B Blackstone Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPLWRVTlA1WWZ3QTVsc3ZWZXpyWFRzNnNyUzhqVmtadk14SC13S0dzVDJRelZZWUs5V3pHcHFraTVLWk55a3EyazZmZjlyOW5TVlZjRVQxbDI3cTF2eElfa1RnZnFGUFRJUHNnWWZrQUdDcEhVamE1aVZOTVEtZGJhcGVyT2Y?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Rallies As Street Backs Zumilokibart Breakthrough", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPTnpQZnBqRHNKbVI1UVlQYmhDVzdtUmp2ZWZPd1dmTV9GcXI2TEVMRjNidzI4eW9VUXNsZ2ZRbThaNHI0RUlXejBwWC16T0E0cmN4cGl6d29raWxOSG5UV1dFOWVzLXNGcmk5SG11SnF6N3ZEbnV5MVp1THVrUkVXbA?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie to acquire Apogee Therapeutics (NASDAQ: APGE) in $10.9B cash deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNS3J2MlZQNThSU0diTzhkVE41MGdObDhTRlkyVUJMV3BGdXN1WXNWa3phOWlBUmlMVlBxTGxCMHRUbHNBRFg0d0ZiZlNpSGxvTjlnS3B4Nms4T1ZCWlBBUWVOeUdRX3RFelplTDJ0WjB5V2VtN3hxb2c3SHBrMWV6NFRSaVYzSEZzZWVNR0M1SFViVHRDaDh4OEZOQUU5dnlRVFplMUZSOUwyeW45VDZUejdB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE (NASDAQ: APGE) files Form 144 listing recent 10b5-1 sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPYURqdHJzZ1Y1WmJYNTVWcTg5R3A0emYxV24yVk5XbE9LaFVRYUV2cUhjVVhmT0FCYmhockw4ZXEzNmJOdFJCTnhSSXEzbmw2cjZ1V2ZDSEl2WWZSWnVJa3pxdUszV25ld3ltZ2gzQjNuMHpMNHYxVEVuc0RqaUJRMFZPYUpuNFAwUUFkQ1c2bFFUNHAxOHhNcWR5RG15R3k5MkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVGpFMmJScFBSTEU5SkZXeEluaFQ4cHBPY1JmeXVUc2w5cDEyMHpQbUVpRE5GMl9wbUhqRzZqUFlnMkRnWERhNnItVzVmWDd0WWZmRU1nRDNadWNnQUhVNTN4NXhkaFJSOXVNZFRyb2pyalI5VGZRZFp0ODVxWURlZ0w0dDJpNUl6Q2Fta0tDTWQtRko4NDZR?oc=5", "source_name": "CNBC", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Climbs As Zumilokibart Data And Blackstone Deal Reprice The Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNZ1lwWVpseHo5MDVFRjVsRHBhSjVXX1FWbWd2ajlPZ3JWX3YwNWZyTk83elU2NG5oczBfU2tmN1p1blFSNG14UHBwZk1Yc0J4NVN0ZkpCX2dGcGpjMndMbHZJRklpTy1zNGlyTkVaN1JBZzJfV3FLSWFVSFV0SkNPRWZlemhmcnV2?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOZk93bkRYeG9lZnlUWGlfWWsweDVFSGRXV1NuWFZnaW5admhybl9IcXpXNS00NmI1QU5FM2VVRW9wQzBZVkQ0T25rcHoyOU4xeWtQc0cyaWQwZXdQZ1JWZUFINHdfRkJIWG1fUl83ekZsVE1Mb3Rac3Q0bWszdG8tbjJyR0x5cFZzZ1lwNS0zOC1lQUNtLWttcTlzUDZKMmExc3c?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APGE Stock Climbs As Wall Street Bets On Zumilokibart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPTkd6a1RVMEFXLS1EdXlzUzItbTYtS1JfeUVGMWk3NE1SOVp4ellrLVBueTVieXdQY25ZUFc0bFJuTmlHRkFMa1ltMHFLTEtYcEFnYU1LQmc1azdHbWg2bmh1WWtZZ0oySU14Y25DaWVONkFMdUsxdmpONmRZdTgtSjR3?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics (APGE) links 7,657-share option grant to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxONnAxQ0JuRGNJQjFqWC1XZ09XRGpMQkMzOGE3NVNuUUVsZkpOdEV2Z3pyWkNJTGs2Vy00Ym43RUhkV2pGdkhNVVpTLXFQWXNvUWhNVzZabVF5OUNsNS1UMnJubzZ5cHBzUmpYYXJMVEhyVTNJQnBWN1B0bi1rNEdPUm1GUm5uOUszX3lLaF9td3dGaHFINFBaM3JqY0VJR2RJRWdJQ2RUSzI0dWNYTXpaLXFMQVhyRDlx?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaEZIYnc0dXlYS0RKYmtFRU1EX20wVjVGT0x3Y3JzSUJ1SDBXbGFnbFItOENpbjNxd0xOTU1UdlBvNWdmYmg2a3FLbGxaVndFT2ZSUFQ1bF8xbnZlSktsenJtNGJ2VTNBM1BoTFhhNmh2cTUtTE5rXzdWMUI3b1NVSEZaZzJSR1BGUmVkZFpXeFc5MHJvbEVLZW5VOVI1Vk9YTkdVRUtVT3c?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Apogee raises $403M after underwriters buy extra shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdnJPdWtaZmxWQVFqMmtnT1hwa2VrMW9CMkQtbnhmZTdXM0xDSngwX3VPdFRrenFVQ0pHVmRkRmtfZ2dIWjlacmlyTUhDTDRFMnRHRVBERm5QNUpzczA0RDJVZFUyUDZTdmJpcW9lbUs1bndfaklsRk1UZG1GZno0bHFIT0R3YnFwN2NReXZ5S1dheW9hZklWWEcxbTVNcGlHZXAtQlpoS2Y4bEhhX0hHekNZSXNYTFd1cVRJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 73, "sentiment_summary": {"positive": 17, "negative": 6, "neutral": 50, "score": 54, "total": 73, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 24.7, "count": 43}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 134.0, "latest_week": "2026-07-17", "one_week_move": 0.3, "four_week_move": 48.3, "twelve_week_move": 56.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.703836, "market_dynamics_buy_signal": false, "relative_strength": 73.05212, "fair_value_gap": 168.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.4409, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.3% over one week, +48.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "Investing.com", "count": 4}, {"label": "Motley Fool", "count": 3}, {"label": "timothysykes.com", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "StocksToTrade", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 65}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 43}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 8}, {"label": "Capital return", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "65", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.3% over one week, +48.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Apogee Therapeutics stock hits all-time high at 134.34 USD"}], "updated_at": "2026-07-22T09:50:44.155960+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}